Temozolomide and capecitabine regimen as first-line treatment in advanced gastroenteropancreatic neuroendocrine tumors at a Latin American reference center
TEMCAP therapy is a viable first-line option regarding efficacy and tolerability in areas where standard therapy is inaccessible.
Authors
- J.C. Haro Varas (ORCID: https://orcid.org/0000-0003-0678-585X)
- Raúl Mantilla
- Jesús R. Medina (ORCID: https://orcid.org/0000-0003-0274-3257)
- Victor Paitan (ORCID: https://orcid.org/0000-0003-1120-4335)
- Victor Castro Oliden (ORCID: https://orcid.org/0000-0003-2828-7325)
- Raymundo Flores
- Wagner Eduardo Cruz-Diaz (ORCID: https://orcid.org/0009-0006-8138-4430)
Institutions
- Instituto Nacional de Enfermedades Neoplásicas (PE)
Publication Details
- Journal
- World Journal of Gastrointestinal Oncology
- Published
- 2024-11-08
- DOI
- https://doi.org/10.4251/wjgo.v16.i12.4675
- Citations
- 1
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.39